Tag Archives: dna

DNA Synthesis Market to hit USD 20.5 Bn by 2032, says Global Market Insights Inc. – GlobeNewswire

Posted on by

Selbyville, Delaware, April 22, 2024 (GLOBE NEWSWIRE) -- DNA Synthesis Market size is expected to reach a remuneration of USD 20.5 billion by 2032. Rising advancements in biotechnology and genetic engineering across various research, diagnostic, and therapeutic applications will augment the industry growth.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/6000

With the rise of precision medicine and personalized healthcare, there is a growing need for custom-designed DNA sequences tailored to specific research objectives or patient requirements. For instance, in March 2024, global genomics solutions provider Integrated DNA Technologies (IDT) expanded its gene synthesis offerings by introducing a new custom vector onboarding tool. The advancing fields of synthetic biology and gene editing techniques, such as CRISPR-Cas9 have further propelled the demand for DNA synthesis, as researchers seek to engineer novel organisms and develop innovative therapies for various diseases.

Collaborations between academic institutions, biotechnology companies, and pharmaceutical firms are also facilitating the development of cutting-edge technologies and streamlined workflows in DNA synthesis. These partnerships foster innovation and knowledge exchange, driving advancements in the methodologies while expanding the repertoire of available synthetic DNA products. Furthermore, the increasing affordability and accessibility of DNA synthesis services, coupled with improvements in synthesis throughput and scalability are democratizing access to synthesized DNA for researchers worldwide.

Rising usage for diagnostics

DNA synthesis market share from the therapeutic application segment is slated to gain momentum through 2024-2032. This is driven by the increasing adoption of molecular diagnostics for disease detection and personalized treatment approaches. Custom-designed DNA sequences help in the development of molecular diagnostic tests, enabling precise detection of genetic mutations and biomarkers associated with various diseases. The advent of targeted therapies and gene editing technologies has also fueled the demand for synthesized DNA in therapeutic applications.

CRO segment to gain traction

The DNA synthesis market from the contract research organization (CRO) segment is expected to expand exponentially up to 2032. This is driven by specialized expertise and infrastructure for DNA synthesis services for catering to the diverse needs of pharmaceutical, biotechnology, and academic research institutions. These organizations possess state-of-the-art facilities equipped with high-throughput synthesis platforms and experienced scientific teams capable of delivering custom-designed DNA sequences with precision and efficiency. CROs also provide end-to-end solutions, including gene synthesis, cloning, and sequence verification, allowing clients to focus on their core research objectives while entrusting the synthesis process to specialized professionals.

Asia Pacific to emerge as a prominent industry

Asia Pacific DNA synthesis market is estimated to record significant valuation by 2032, attributed to the increasing investment in genomics research and biotechnology initiatives by governments and private enterprises across countries like China, Japan, and India. The rising prevalence of genetic disorders and infectious diseases in the region has spurred the demand for customized DNA sequences for diagnostic and therapeutic applications. Advancements in healthcare infrastructure and the growing adoption of precision medicine will further stimulate the regional industry growth.

Request for Report Customization @https://www.gminsights.com/roc/6000

DNA Synthesis Industry Players

Some of the prominent DNA synthesis market players include Thermo Fisher Scientific, Inc., ELISA experts, Twist Bioscience, BOSTER antibody, Bioneer Corporation, ProteoGenix, Eton Bioscience, BIOMATIK, LGC Biosearch Technologies, ProMab Biotechnologies, IBA GmbH, Eurogentec, Eurofins Scientific, Quintara Biosciences OriGene Technologies, Inc., Integrated DNA Technologies, Inc.and GenScript Biotech Corporation.

These firms are focusing on partnership ventures and innovations to proliferate their product portfolio and customer base. To cite an instance, in August 2023, Genscript Biotech formed a strategic collaboration agreement with T-MAXIMUM Biotech to develop CAR-T cell therapy.

Partial Table of Contents (ToC) of the report:

Chapter 2Executive Summary

2.1 Global DNA synthesis market 360 synopsis, 2018 2032 2.1.1 Business trends 2.1.2 Regional trends 2.1.3 Service trends 2.1.4 Method trends 2.1.5 Application trends 2.1.6 End-use trends Chapter 3DNA Synthesis Industry Insights 3.1 Industry ecosystem analysis 3.2 Industry impact forces 3.2.1 Growth drivers 3.2.1.1Growing prevalence of diseases globally 3.2.1.2Rapid technology advancements in the field of synthetic biology 3.2.1.3Rising investments towards research and development(R&D) activities 3.2.2 Industry pitfalls & challenges 3.2.2.1Stringent government regulations and guidelines 3.2.2.2High cost, potential biosafety,biosecurity and ethical issues 3.3 Growth potential analysis 3.3.1 By service 3.3.2 By method 3.3.3 By application 3.3.4 By end use 3.4 COVID- 19 impact analysis 3.5 Regulatory landscape 3.5.1 U.S. 3.5.2 Europe 3.6 Porter's analysis 3.7 PESTEL analysis

Browse Our Reports Store - GMIPulse @ https://www.gminsights.com/gmipulse

About Global Market Insights

Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy, and biotechnology.

Read more here:

DNA Synthesis Market to hit USD 20.5 Bn by 2032, says Global Market Insights Inc. - GlobeNewswire

This astronaut took 5 spacewalks. Now, he’s helping make spacesuits for future ISS crews (exclusive) – Space.com

Posted on by

The next generation of spacesuits for astronauts just went parabolic.

Collins Aerospace tested its new spacesuit design, built for International Space Station spacewalks, on a parabolic flight that simulated microgravity conditions. The goal was to fulfill requirements for a NASA contract aimed at replacing the long-standing extravehicular mobility units (EMUs) now used on the orbiting complex.

Following the news release on Feb. 1, Collinschief test astronaut John "Danny" Olivas a retired NASA astronaut spoke with Space.com about the company's plans for the floating suit. He also discussed exciting possibilities for moon exploration. Read on to learn more about how Olivas is using his past spacewalking experience to pave the way for future spacewalkers.

Collins received a 2022 task order from NASA to develop a next-generation EMU to be lighter and more flexible than current spacesuits. These suits are also under consideration to become moonwalking outfits for the agency's Artemis program; the design team received a separate task order in July 2023 to modify the floating-style spacesuits for surface excursions.

Related: Watch next-generation lightweight spacesuit tested on Zero-G flight (photos, video)

Space.com: What sorts of experiences were you able to port from your time at NASA to Collins, to help with the development?

Danny Olivas: I've been an engineer for over 35 years. I've always been fascinated about space. It is very much like coming home and being part of an engineering family where we toil away to produce things that are safe, efficient and effective for our clients.

The intent is basically, "right design" this suit. It should be a suit that is intuitive to the astronauts. So I feel like what I'm bringing to the table is essentially helping the engineers understand what is important, where do things need to be placed, what are the things that you need to be considering. For example, in December of last year, we completed an exercise called the "concept of operations." That essentially is evaluating the suit in an environment like you're integrated onto a spacewalk and then coming back from doing a spacewalk.

I was able to bring to the table: when we do our prep and post, here's what we do. Here's what we did on orbit. Here's how we work to this particular issue. Through that exercise, it provided feedback directly to the engineers on how to move forward. It's not a one and done thing. It's a collaboration: we've gone, and taken a look at that, and we can do this or we can't do that.

Related: Shuttle astronaut Danny Olivas talks diversity on Earth (and space) in 'Virtual Astronaut' webcast

I feel like I'm bringing everything I can to this. This likely going to be my last job, and I'm going to be on the field. I care about the astronauts: that we're building the spacesuits for the people who got me five spacewalks, and did so in a safe manner. I owe it to them, to give back to the engineering community: everything I can to help our team be successful and provide the safest and most efficient, most effective spacesuit for the next generation of explorers. That's the very least I owe for being given the opportunity.

Space.com: Can you step us through the development?

Olivas: Collins, with our partners ILC Dover Astrospace and Oceaneering, use heritage or legacy from the original Hamilton Standard suit technology, which is something that's been ingrained in the company DNA from the Apollo missions. The A7L spacesuit was the first one that was formed, all the way through the current EMU. It makes perfect sense that we are looking at extending to the next generation spacesuit for the International Space Station.

The intent is for NASA delivery and, at that point, we'll have a new suit on the space station that will not only be for the space station, but also will be applicable for other commercial destinations after ISS. That includes lunar landings as well; as you're familiar with, Axiom Space won the contract for the lunar suit and they're destined for their launch on (first moon landing) Artemis 3. We wish them the very best of luck. But we're also making a suit that's compatible with lunar applications. We look to be a continued competitor in the lunar space as well, because that is the future of exploration.

Space.com: What happened during the parabolic campaign?

Olivas: This campaign actually began over a year ago, when it was first decided that we would conduct a portion of the crew capability assessment in a microgravity environment. There's no 1 G equivalent that would give you confidence that the things that you would be doing could be applicable in microgravity. We looked at some of the more challenging things, such as airlock egress and ingress. Collins has built a mockup that was to scale.

Getting this this new suit across the hatch was vital to demonstrate that you have the ability to be able to do so, and the geometry of the suit would in fact actually go through there. So that was a big risk, especially if you consider that you only have a parabola to be able to demonstrate that. Sometimes getting in and out of the airlock can take upwards of a couple of minutes, but you don't get that liberty if you're doing a zero-G flight.

Related: I flew weightlessly on a parabolic flight to see incredible student science soar

The answer to that is practice, practice, practice, practice, practice, practice. We were literally, on a weekly basis, writing the choreography of what we would do on each and every parabola. Every team member was there. We knew where we were going to be positioned. The whole idea was that you want to be out of the way when it's time to go to the task, when there's limited time to be able to do that. And it worked flawlessly.

I learned some things. Trying to stand on your feet on a footplate makes it a bit challenging, so for me, it was trying to learn how to operate in this I would call it a bronco, if you will. Certainly there were oscillations. But we were still able to demonstrate that you could get inside a portable foot restraint within 20 seconds.

Space.com: Can you give a comparison about what it's like to be working in the current EMU compared with what Collins is going to be able to offer?

Olivas: From the outside, probably not a lot. You're going to see two arms, two legs, a helmet and a layer of white. The secret sauce is below that layer of white. There's no technology that's carried over from the EMU, but what has been carried over is all the lessons learned against this concept in doing this from day one. We bring all that experience and heritage with the suit into the development designers.

Now let's talk about the difference between the EMU and the next generation suit. It is like night and day. I'm talking strictly right now from the PGS the pressure garment system, the mobility aspect of it. Things that would lock you up in the suit on orbit. By the way, lockup issues especially with shoulder joints are part of the reason why we had an injury rate.

As we think of accessibility to the lunar application, we have intentionally gotten rid of a component called the waist bearing assembly, the ability to essentially pivot around the waist. In exchange we have introduced hip joints, joints which work in unison to allow for walking. This gives us a lot more flexibility in the lower extremities. I think the increasing range of motion, increased maneuverability are probably the biggest attributes that I've seen.

Space.com: Anything else would you like to add?

Olivas: I would say, help me carry forward the message about what the suit is. As much as this machine is to keep the human being alive in the space like solo spacecraft it's the contributions that make it right. It's all those engineers who go through kind of an anonymous perspective in their entire career, and you're never really knowing what they do. But it just happens because of a human being behind it. That team, I'm part of today, and I want to make sure that that becomes clear.

This interview was edited and condensed. This article was amended at 2:15 p.m. EST Feb. 14 to add information about other companies involved with the Collins spacesuit and to address a typo.

Go here to see the original:

This astronaut took 5 spacewalks. Now, he's helping make spacesuits for future ISS crews (exclusive) - Space.com

Patients’ perceptions and practices of informing relatives: a qualitative study within a randomised trial on healthcare … – Nature.com

Posted on by

Prince AE, Cadigan RJ, Henderson GE, Evans JP, Adams M, Coker-Schwimmer E. et al. Is there evidence that we should screen the general population for Lynch syndrome with genetic testing? A systematic review. Pharmacogenomics Pers Med.2017;10:4960.

CAS Google Scholar

Nelson HD, Pappas M, Cantor A, Haney E, Holmes R. Risk Assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: updated evidence report and systematic review for the US Preventive Services Task Force. Jama. 2019;322:66685.

Article PubMed Google Scholar

Monahan KJ, Bradshaw N, Dolwani S, Desouza B, Dunlop MG, East JE, et al. Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG). Gut. 2020;69:41144.

Article CAS PubMed Google Scholar

Young AL, Imran A, Spoelma MJ, Williams R, Tucker KM, Halliday J, et al. Proband-mediated interventions to increase disclosure of genetic risk in families with a BRCA or Lynch syndrome condition: a systematic review. Eur J Hum Genet. 2023;31:1834.

Article CAS PubMed Google Scholar

Ahsan MD, Levi SR, Webster EM, Bergeron H, Lin J, Narayan P, et al. Do people with hereditary cancer syndromes inform their at-risk relatives? A systematic review and meta-analysis. PEC Innov. 2023;2:100138.

Article PubMed PubMed Central Google Scholar

Gaff CL, Collins V, Symes T, Halliday J. Facilitating family communication about predictive genetic testing: probands perceptions. J Genet Couns. 2005;14:13340.

Article PubMed Google Scholar

Frey MK, Ahsan MD, Bergeron H, Lin J, Li X, Fowlkes RK, et al. Cascade testing for hereditary cancer syndromes: should we move toward direct relative contact? A systematic review and meta-analysis. J Clin Oncol. 2022;40:412943.

Article PubMed PubMed Central Google Scholar

Menko FH, van der Velden SL, Griffioen DN, Ait Moha D, Jeanson KN, Hogervorst FBL, et al. Does a proactive procedure lead to a higher uptake of predictive testing in families with a pathogenic BRCA1/BRCA2 variant? A family cancer clinic evaluation. J Genet Couns. 2023 [Internet]. Aug 21. Available from: https://www.ncbi.nlm.nih.gov/pubmed/37605508.

National clinical guidelines of breast cancer management [Internet]. Confederation of Regional Cancer Centres in Sweden. [cited 2023 Sept 10]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/brostcancer/vardprogram/.

National clinical guidelines of colorectal cancer management [Internet]. Confederation of Regional Cancer Centres in Sweden. [cited 2023 Sept 10]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/tjock-och-andtarmscancer/vardprogram/.

Hawranek C, Ehrencrona H, Ofverholm A, Hellquist BN, Rosen A. Direct letters to relatives at risk of hereditary cancer-study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study). Trials. 2023;24:810.

Article PubMed PubMed Central Google Scholar

Braun V, Clarke V. Reflecting on reflexive thematic analysis. Qual Res Sport, Exerc Health. 2019;11:58997.

Article Google Scholar

Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77101.

Article Google Scholar

Forrest K, Simpson SA, Wilson BJ, van Teijlingen ER, McKee L, Haites N, et al. To tell or not to tell: barriers and facilitators in family communication about genetic risk. Clin Genet. 2003;64:31726.

Article CAS PubMed Google Scholar

Gaff CL, Clarke AJ, Atkinson P, Sivell S, Elwyn G, Iredale R, et al. Process and outcome in communication of genetic information within families: a systematic review. Eur J Hum Genet. 2007;15:9991011.

Article PubMed Google Scholar

McGarragle KM, Hare C, Holter S, Facey DA, McShane K, Gallinger S, et al. Examining intrafamilial communication of colorectal cancer risk status to family members and kin responses to colonoscopy: a qualitative study. Hered Cancer Clin Pr. 2019;17:16.

Article Google Scholar

Henrikson NB, Blasi P, Figueroa Gray M, Tiffany BT, Scrol A, Ralston JD, et al. Patient and family preferences on health system-led direct contact for cascade screening. J Pers Med. 2021;11:538.

Article PubMed PubMed Central Google Scholar

Pedrazzani C, Aceti M, Schweighoffer R, Kaiser-Grolimund A, Brki N, Chappuis PO, et al. The communication chain of genetic risk: analyses of narrative data exploring probandprovider and probandfamily communication in hereditary breast and ovarian cancer. J Pers Med. 2022;12:1249.

Article PubMed PubMed Central Google Scholar

Srinivasan S, Won NY, Dotson WD, Wright ST, Roberts MC. Barriers and facilitators for cascade testing in genetic conditions: a systematic review. Eur J Hum Genet. 2020;28:163144.

Article PubMed PubMed Central Google Scholar

Daly MB. Family communication of genetic risk: a personalized approach. Curr Genet Med Rep. 2016;4:3540.

Article Google Scholar

Finn KS, Pacyna J, Azevedo Tsou C, Jewel Samadder N, Sharp R. Patient-reported anticipated barriers and benefits to sharing cancer genetic risk information with family members. Eur J Hum Genet. 2022;30:5361.

Article PubMed Google Scholar

Srinivasan S, Hampel H, Leeman J, Patel A, Kulchak Rahm A, Reuland DS, et al. Stakeholder perspectives on overcoming barriers to cascade testing in Lynch syndrome: a qualitative study. Cancer Prev Res. 2020;13:103746.

Article Google Scholar

Ballard LM, Band R, Lucassen AM. Interventions to support patients with sharing genetic test results with at-risk relatives: a synthesis without meta-analysis (SWiM). Eur J Hum Genet. 2023;31:9881002.

Article PubMed PubMed Central Google Scholar

Mendes A, Paneque M, Sousa L, Clarke A, Sequeiros J. How communication of genetic information within the family is addressed in genetic counselling: a systematic review of research evidence. Eur J Hum Genet. 2016;24:31525.

Article PubMed Google Scholar

Vos J, Menko F, Jansen AM, van Asperen CJ, Stiggelbout AM, Tibben A. A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Fam Cancer. 2011;10:8796.

Article PubMed Google Scholar

Jacobs C, Dancyger C, Smith JA, Michie S. Accuracy of recall of information about a cancer-predisposing BRCA1/2 gene mutation among patients and relatives. Eur J Hum Genet. 2015;23:14751.

Article CAS PubMed Google Scholar

van den Heuvel LM, Hoedemaekers YM, Baas AF, Baars MJH, van Tintelen JP, Smets EMA, et al. A tailored approach to informing relatives at risk of inherited cardiac conditions: results of a randomised controlled trial. Eur J Hum Genet. 2022;30:20310.

Article PubMed Google Scholar

Jacobs C, Patch C, Michie S. Communication about genetic testing with breast and ovarian cancer patients: a scoping review. Eur J Hum Genet. 2019;27:51124.

Article PubMed Google Scholar

van den Heuvel LM, Smets EMA, van Tintelen JP, Christiaans I. How to inform relatives at risk of hereditary diseases? A mixed-methods systematic review on patient attitudes. J Genet Couns. 2019;28:104258.

Article PubMed Google Scholar

Eijzenga W, de Geus E, Aalfs CM, Menko FH, Sijmons RH, de Haes H, et al. How to support cancer genetics counselees in informing at-risk relatives? Lessons from a randomized controlled trial. Patient Educ Couns. 2018;101:16119.

Article PubMed Google Scholar

Pedrazzani C, Ming C, Burki N, Caiata-Zufferey M, Chappuis PO, Duquette D, et al. Genetic literacy and communication of genetic information in families concerned with hereditary breast and ovarian cancer: a cross-study comparison in two countries and within a timeframe of more than 10 years. Cancers. 2021;13:6254.

Article PubMed PubMed Central Google Scholar

Paul J, Metcalfe S, Stirling L, Wilson B, Hodgson J. Analyzing communication in genetic consultations-a systematic review. Patient Educ Couns. 2015;98:1533.

Article PubMed Google Scholar

Henrikson NB, Blasi PR, Fullerton SM, Grafton J, Leppig KA, Jarvik GP, et al. It would be so much easier: health system-led genetic risk notification-feasibility and acceptability of cascade screening in an integrated system. J Community Genet. 2019;10:46170.

Article PubMed PubMed Central Google Scholar

Dheensa S, Fenwick A, Lucassen A. Is this knowledge mine and nobody elses? I dont feel that. Patient views about consent, confidentiality and information-sharing in genetic medicine. J Med Eth. 2016;42:1749.

Article Google Scholar

Tam NT, Huy NT, Thoa le TB, Long NP, Trang NT, Hirayama K, et al. Participants understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bull World Health Organ. 2015;93:18698H.

Article PubMed PubMed Central Google Scholar

Blasi PR, Scrol A, Anderson ML, Gray MF, Tiffany B, Fullerton SM, et al. Feasibility, acceptability, and limited efficacy of health system-led familial risk notification: protocol for a mixed-methods evaluation. Pilot Feasibility Stud. 2022;8:174.

Article PubMed PubMed Central Google Scholar

Kim S, Aceti M, Baroutsou V, Burki N, Caiata-Zufferey M, Cattaneo M, et al. Using a Tailored Digital Health Intervention for family communication and cascade genetic testing in Swiss and Korean families with hereditary breast and ovarian cancer: protocol for the DIALOGUE study. JMIR Res Protoc. 2021;10:e26264.

Article PubMed PubMed Central Google Scholar

Siglen E, Vetti HH, Augestad M, Steen VM, Lunde A, Bjorvatn C. Evaluation of the Rosa chatbot providing genetic information to patients at risk of hereditary breast and ovarian cancer: qualitative interview study. J Med Internet Res. 2023;25:e46571.

Article PubMed PubMed Central Google Scholar

Read more from the original source:

Patients' perceptions and practices of informing relatives: a qualitative study within a randomised trial on healthcare ... - Nature.com

Unlocking the Genetic Puzzle of Obesity Across Sexes and Ages – SciTechDaily

Posted on by

A study has identified genes that influence obesity risk differently across sexes and age groups, offering new insights into the biological pathways of obesity. These discoveries underscore the importance of considering sex and age in obesity research and could lead to new treatments.

Researchers have discovered genes that impact obesity risk differently in men and women and across various ages, revealing potential new pathways for understanding and treating obesity.

From influencing how our body stores fat to how our brain regulates appetite, hundreds of genes, along with environmental factors, collectively determine our weight and body size. Now, researchers add several genes, that appear to affect obesity risk in certain sexes and ages, to that list. The study, published in the journal Cell Genomics, may shed light on new biological pathways that underlie obesity and highlight how sex and age contribute to health and disease.

There are a million and one reasons why we should be thinking about sex, age, and other specific mechanisms rather than just lumping everyone together and assuming that disease mechanism works the same way for everyone, says senior author John Perry, a geneticist and professor at the Wellcome-MRC Institute of Metabolic Science, University of Cambridge, U.K. Were not expecting people to have completely different biology, but you can imagine things like hormones and physiology can contribute to specific risks.

To untangle sexs role in obesity risk, the research team sequenced the exomethe protein-coding part of the genomeof 414,032 adults from the UK Biobank study. They looked at variants, or mutations, within genes associated with body mass index (BMI) in men and women, respectively. Based on height and weight, BMI is an estimated measurement of obesity. The search turned up five genes influencing BMI in women and two in men.

Researchers identified age-specific and sex-specific obesity genes by looking into the genome of 414,032 people from the UK. Credit: Cell Genomics/Kaisinger et al.

Among them, faulty variants of three genesDIDO1, PTPRG, and SLC12A5are linked to higher BMI in women, up to nearly 8 kg/m more, while having no effect on men. Over 80% of the women with DIDO1 and SLC12A5 variants had obesity, as approximated by their BMI. Individuals carrying DIDO1 variants had stronger associations with higher testosterone levels and increased waist-to-hip ratio, both risk indicators for obesity-related complications like diabetes and heart disease. Others with SLC12A5 variants had higher odds of having type 2 diabetes compared with non-carriers. These findings highlight previously unexplored genes that are implicated in the development of obesity in women but not men.

Perry and his colleague then repeated their method to look for age-specific factors by searching for gene variants associated with childhood body size based on participants recollections. They identified two genes, OBSCN and MADD, that were not previously linked to childhood body size and fat. While carriers of OBSCN variants had higher odds of having higher weight as a child, MADD variant carriers were associated with smaller body sizes. In addition, the genetic variants acting on MADD had no association with adult obesity risk, highlighting age-specific effects on body size.

Whats quite surprising is that if you look at the function of some of these genes that we identified, several are clearly involved in DNA damage response and cell death, says Perry. Obesity is a brain-related disorder, whereas biological and environmental factors act to influence appetite. Theres currently no well-understood biological paradigm for how DNA damage response would influence body size. These findings have given us a signpost to suggest variation in this important biological process may play a role in the etiology of obesity.

Next, the research team hopes to replicate the study in a larger and more diverse population. They also plan to study the genes in animals to peer into their function and relationship with obesity.

Were at the very earliest stages of identifying interesting biology, says Perry. We hope the study can reveal new biological pathways that may one day pave the way to new drug discovery for obesity.

Reference: Large-scale exome sequence analysis identifies sex- and age-specific determinants of obesity by Lena R. Kaisinger, Katherine A. Kentistou, Stasa Stankovic, Eugene J. Gardner, Felix R. Day, Yajie Zhao, Alexander Mrseburg, Christopher J. Carnie, Guido Zagnoli-Vieira, Fabio Puddu, Stephen P. Jackson, Stephen ORahilly, I. Sadaf Farooqi, Laura Dearden, Lucas C. Pantaleo, Susan E. Ozanne, Ken K. Ong and John R.B. Perry, 2 August 2023, Cell Genomics. DOI: 10.1016/j.xgen.2023.100362

Excerpt from:

Unlocking the Genetic Puzzle of Obesity Across Sexes and Ages - SciTechDaily